ANA Highlights - Bite Size Learning (CME)

ANA Highlights - A New Bite-Size Learning Program from the ANA!

Micro- or Bite Size Learning is the new craze in online education. The ANA Education Innovation Subcommittee is excited to announce the launch of an ANA Bite Size Learning program in 2020. ANA members are offered the opportunity to claim AMA PRA Category 1 CreditsTM for eligable modules.  

ANA Highlights producers & planners: Deanna Saylor, MD, MHS, Johns Hopkins University (program lead); Romergryko G. Geocadin, MD, Johns Hopkins University; Danny Bega, MD, Northwestern University; Megan Richie, MD, University of California, San Francisco; Jim Siegler, MD, Cooper Hospital; and Jen Hurley, CHCP, CPHQ, ANA Acceditation & Education Manager.

Have an idea for a module? For our Bite Size Learning program, the ANA will schedule time to virtually record 10-15 minute presentations with guest lecturers. If you have an idea for a presentation, maybe an important update about your work, a call to action for others to join you in working on a particular initiative, or another hot topic in the world of academic research, please submit your ideas here.

 

CME Information

The American Neurological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Neurological Association designates each enduring material for a maximum number of AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The planners and faculty for this activity have no relevant relationships to disclose unless listed below.

 

Available Modules

COVID-19: Shining a Light on the Global Burden of Neurological Disease
In this 19-minute presentation, Dr. Deanna Saylor Assistant Professor of Neurology, Director, Hopkins Global Neurology Program at the Johns Hopkins University School of Medicine and currently on assignment in Zambia, talks us through how the current pandemic environment elevates the importance of partnering globally to learn from each other, acting globally by taking assignments in areas in most need, and thinking globally by considering where global perspectives may improve research. All, so we may together, tackle neurologic conditions that continue to cause disability and mortality in patients all over the world. CME value: .5 AMA PRA Category 1 CreditsTM
Watch Video | CME


The Path Forward: Academic Neurology Responds to COVID-19
In this 38 minute video, we hear insights from Justin C. McArthur, MBBS, MPH, President, American Neurological Association, and John W. Griffin Professor of Neurology and Director, Department of Neurology at Johns Hopkins Medicine on how we might approach the future amid COVID-19. Watch Video


Stroke Guidance in the COVID-19 Pandemic
During this 36-minute video, Dr. Thanh Nguyen takes us through the origin of COVID-19 and its impact on stroke care - both for patients and clinicians. Note: Dr. Nguyen obtained permission to use the images used in this presentation and offered disclosures at the start of the presentation. CME value: .75 AMA PRA Category 1 CreditsTM
Watch Video | CME


Extraneuronal Phenotypes of Spinal Muscular Atrophy: Part 1
In this 12-minute video, Dr. Basil Darras, Professor of Neurology at Boston Children’s Hospital and Harvard Medical School, introduces the learner to spinal muscular atrophy (SMA), the number one genetic cause of death in infants. SMA is a genetic disorder characterized by degeneration and loss of motor neurons in the anterior horns of the spinal cord and brain stem of children and adults, with limited involvement of peripheral organs in severely affected patients. What are the extra-neuronal phenotypes of SMA in humans and animal models? Part 1 of 2. CME value: .25 AMA PRA Category 1 CreditsTM
Watch Video | CME

 
Extraneuronal Phenotypes of Spinal Muscular Atrophy: Part 2
In part 2 of this series, Dr. Crystal Yeo, Assistant Professor at LKC School of Medicine, Associated Staff at Boston Children’s Hospital, joint Medical Director at EDDC and Group Leader at IMCB, continues on to review the changing therapeutic landscape for spinal muscular atrophy (SMA), the extra-neuronal expression of survival motor neuron (SMN) protein, and motor neuron cell-non-autonomous rescue in animal models. What are the clinical implications for patients treated with SMN protein augmenting interventions? In the era of innovative therapies, why is it important for physicians, scientists and others to be aware of the potential emergence of extra-neuronal phenotypes in treated SMA patients?  Part 2 of 2. CME value: .25 AMA PRA Category 1 CreditsTM
Watch Video | CME


Huntington Disease Updates
In this 19-minute video, Dr. Jee Bang provides an overview of the current state of research and therapy for Huntington Disease. CME value: .5 AMA PRA Category 1 CreditsTM
Watch Video | CME

  • Dr. Bang provided disclosures at the start of her presentation